SciVision Biotech Inc. (TPE:1786)
Taiwan · Delayed Price · Currency is TWD 49.55
0.00 (0.00%)
Aug 19, 2026, 1:30 PM CST
SciVision Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 178.11 | 162.34 | 242.25 | 177.9 | 141.72 | 101.72 |
Depreciation & Amortization | 87.59 | 80.36 | 65.14 | 63.05 | 62.02 | 52.98 |
Other Amortization | 0.08 | 0.07 | 0.08 | 0.08 | 0.04 | 0.04 |
Loss (Gain) From Sale of Assets | 0 | 0.01 | -0.19 | -0.54 | -30.55 | -0.13 |
Loss (Gain) From Sale of Investments | -1.25 | 2.13 | -6.45 | -2.9 | 1.98 | 0.13 |
Other Operating Activities | 18.87 | -4.07 | 25.99 | 7.43 | 18.12 | -2.23 |
Change in Accounts Receivable | -83.65 | -75.5 | -73.55 | -4.85 | -7.77 | -10.47 |
Change in Inventory | -21.31 | -13.74 | 14.45 | 8.62 | -13 | -37.03 |
Change in Accounts Payable | 11.86 | 3.13 | 6.52 | -3.21 | 6.77 | -11.33 |
Change in Unearned Revenue | -4.01 | -1.13 | -4.34 | 6.32 | -1.01 | -5.6 |
Change in Other Net Operating Assets | -67.5 | -29.6 | -0.04 | 20.11 | 3.68 | 10.41 |
Operating Cash Flow | 118.78 | 123.99 | 269.87 | 272.01 | 181.99 | 98.51 |
Operating Cash Flow Growth | -55.08% | -54.06% | -0.79% | 49.47% | 84.75% | -22.11% |
Capital Expenditures | -66.01 | -101.53 | -34.76 | -14.73 | -14.96 | -25.78 |
Sale of Property, Plant & Equipment | 1.11 | - | 0.19 | 1.26 | 56.48 | 21.13 |
Sale (Purchase) of Intangibles | -0.22 | -0.23 | -0.12 | -0.11 | - | - |
Investment in Securities | -105.82 | -39.79 | 134 | -201.79 | -48.49 | -20.89 |
Other Investing Activities | 1.57 | -1.19 | -1.79 | 2.01 | 52.79 | -51.47 |
Investing Cash Flow | -169.36 | -142.74 | 97.52 | -213.37 | 45.81 | -77.01 |
Short-Term Debt Issued | - | 2 | - | - | - | 10 |
Long-Term Debt Issued | - | 400 | - | - | 700 | 1,200 |
Total Debt Issued | 400.5 | 402 | - | - | 700 | 1,210 |
Short-Term Debt Repaid | - | -1.49 | - | - | - | -10 |
Long-Term Debt Repaid | - | -8.1 | -3.35 | -1.23 | -905.89 | -901.39 |
Total Debt Repaid | -14.84 | -9.6 | -3.35 | -1.23 | -905.89 | -911.39 |
Net Debt Issued (Repaid) | 385.66 | 392.4 | -3.35 | -1.23 | -205.89 | 298.61 |
Repurchase of Common Stock | -107.06 | - | - | - | - | - |
Common Dividends Paid | -142.84 | -233.87 | -169.33 | -133.3 | -93.83 | -58.56 |
Other Financing Activities | - | - | 0.16 | - | 0.01 | - |
Financing Cash Flow | 135.77 | 158.53 | -172.52 | -134.53 | -299.71 | 240.06 |
Foreign Exchange Rate Adjustments | 0.22 | 0 | 0.05 | -0.03 | 0.01 | -0.01 |
Net Cash Flow | 85.41 | 139.79 | 194.92 | -75.92 | -71.9 | 261.55 |
Free Cash Flow | 52.77 | 22.46 | 235.11 | 257.28 | 167.03 | 72.73 |
Free Cash Flow Growth | -72.25% | -90.45% | -8.62% | 54.04% | 129.64% | 21.97% |
Free Cash Flow Margin | 5.93% | 2.53% | 26.62% | 36.08% | 29.97% | 14.39% |
Free Cash Flow Per Share | 0.69 | 0.29 | 3.16 | 3.37 | 2.24 | 1.02 |
Levered Free Cash Flow | -163.57 | -82.15 | 134.06 | 189.21 | 99.15 | 9.36 |
Unlevered Free Cash Flow | -156.2 | -77.19 | 137.61 | 194.35 | 103.18 | 14.4 |
Cash Interest Paid | 0.22 | 0.03 | 0.99 | 0.42 | 2.99 | 1.12 |
Cash Income Tax Paid | 25.23 | 38.03 | 28.6 | 30.97 | 11.51 | 23.53 |
Change in Working Capital | -164.62 | -116.84 | -56.96 | 26.99 | -11.33 | -54.01 |